keyword
MENU ▼
Read by QxMD icon Read
search

Apixabane

keyword
https://www.readbyqxmd.com/read/29447773/percutaneous-coronary-intervention-and-antiplatelet-therapy-in-patients-with-atrial-fibrillation-receiving-apixaban-or-warfarin-insights-from-the-aristotle-trial
#1
David Kopin, W Schuyler Jones, Matthew W Sherwood, Daniel M Wojdyla, Lars Wallentin, Basil S Lewis, Freek W A Verheugt, Dragos Vinereanu, M Cecilia Bahit, Sigrun Halvorsen, Kurt Huber, Alexander Parkhomenko, Christopher B Granger, Renato D Lopes, John H Alexander
BACKGROUND: We assessed antiplatelet therapy use and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ARISTOTLE trial. METHODS: Patients were categorized based on the occurrence of PCI during follow-up (median 1.8 years); PCI details and outcomes post-PCI are reported. Of the 18,201 trial participants, 316 (1.7%) underwent PCI (152 in apixaban group, 164 in warfarin group). RESULTS: At the time of PCI, 84% (267) were on study drug (either apixaban or warfarin)...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29447769/apixaban-following-acute-coronary-syndromes-in-patients-with-prior-stroke-insights-from-the-appraise-2-trial
#2
Matthew W Sherwood, Renato D Lopes, Jie Lena Sun, Danny Liaw, Robert A Harrington, Lars Wallentin, Daniel T Laskowitz, Stefan K James, Shaun G Goodman, Harald Darius, Basil S Lewis, C Michael Gibson, Karen S Pieper, John H Alexander
BACKGROUND AND PURPOSE: Patients with prior stroke are at greater risk for recurrent cardiovascular events post-acute coronary syndromes (ACS) and may have a different risk/benefit profile with antithrombotic therapy than patients without prior stroke. METHODS: We studied 7391 patients with ACS from APPRAISE-2, stratified by the presence or absence of prior stroke. Baseline characteristics and outcomes of cardiovascular death, myocardial infarction (MI), or stroke were compared between groups...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29441513/evaluation-of-indications-for-reduced-dose-noacs-in-hospitalized-atrial-fibrillation-patients
#3
Olga Jelonek, Iwona Gorczyca, Michał Bączek, Paweł Kośmider, Beata Wożakowska-Kapłon
BACKGROUND: Prevention of thromboembolic complications is a priority in patients with atrial fibrillation (AF). The use of non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOAC) is more common, and some patients have indications for a reduced dose of NOAC. AIM: The aim of the study was to evaluate the frequency of NOACs being prescribed to AF patients and to compare the groups of AF patients receiving standard and reduced doses of NOACs. METHODS: The study was conducted in a population of 1,327 patients diagnosed with AF and hospitalized at an institution of the highest referral level in cardiology in years 2015-2016...
February 14, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29437733/cough-as-the-sole-manifestation-of-pericardial-effusion
#4
Hee Kong Fong, Obai Abdullah, Sandeep Gautam
A 59-year-old woman with paroxysmal atrial fibrillation (AF) presented with severe non-productive cough, malaise, low-grade fever and AF flare-up 3 weeks following pulmonary vein isolation with radiofrequency catheter ablation. She denied chest pain or dyspnoea. Patient was haemodynamically stable. There was no pulsus paradoxus. Laboratories showed leucocytosis and elevated C-reactive protein. ECG showed sinus tachycardia. CT abdomen and pelvis showed a large pericardial effusion (PE). Shortly after admission, she developed AF with rapid ventricular response, responsive to intravenous amiodarone...
February 5, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29433148/international-council-for-standardization-in-haematology-icsh-recommendations-for-laboratory-measurement-of-direct-oral-anticoagulants
#5
Robert C Gosselin, Dorothy M Adcock, Shannon M Bates, Jonathan Douxfils, Emmanuel J Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Edelgard Lindhoff-Last, Steve Kitchen
This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH) for providing haemostasis-related guidance documents for clinical laboratories. This inaugural coagulation ICSH document was developed by an ad hoc committee, comprised of international clinical and laboratory direct acting oral anticoagulant (DOAC) experts. The committee developed consensus recommendations for laboratory measurement of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban), which would be germane for laboratories assessing DOAC anticoagulation...
February 12, 2018: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/29432317/the-outcomes-of-early-surgical-intervention-in-geriatric-proximal-femur-fractures-among-patients-receiving-direct-oral-anticoagulation
#6
Nathan A Franklin, Ashley Ali, Richard K Hurley, Hassan R Mir, Michael J Beltran
OBJECTIVE: Evaluate the pre-hospital use of Direct Oral Anticoagulant (DOAC) agents on the outcomes of early surgical fixation of a geriatric hip fracture. DESIGN: Case-Control. SETTING: Two academic level 1 trauma centers. INTERVENTION: Early (<48h) surgical fixation of a geriatric proximal femur fracture. PATIENTS: 19 patients receiving Pradaxa (Dabigatran), Eliquis (Apixaban), or Xarelto (Rivaroxaban) who underwent surgery between 2010 and 2015 and 74 control patients...
February 9, 2018: Journal of Orthopaedic Trauma
https://www.readbyqxmd.com/read/29419390/dyslipidemia-and-risk-of-cardiovascular-events-in-patients-with-atrial-fibrillation-treated-with-oral-anticoagulation-therapy-insights-from-the-aristotle-apixaban-for-reduction-in-stroke-and-other-thromboembolic-events-in-atrial-fibrillation-trial
#7
Tymon Pol, Claes Held, Johan Westerbergh, Johan Lindbäck, John H Alexander, Marco Alings, Cetin Erol, Shinya Goto, Sigrun Halvorsen, Kurt Huber, Michael Hanna, Renato D Lopes, Witold Ruzyllo, Christopher B Granger, Ziad Hijazi
BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation. METHODS AND RESULTS: Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, ApoA1 and ApoB plasma levels were measured at baseline in 14 884 atrial fibrillation patients...
February 1, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29417256/plasma-clot-formation-and-clot-lysis-to-compare-effects-of-different-anticoagulation-treatments-on-hemostasis-in-patients-with-atrial-fibrillation
#8
Oliver Königsbrügge, Günter Weigel, Peter Quehenberger, Ingrid Pabinger, Cihan Ay
The effect of direct oral anticoagulants (DOACs) on turbidimetric measurements of plasma clot formation and susceptibility to fibrinolysis may facilitate a comparison between different classes of anticoagulants in plasma samples. We obtained 424 citrate plasma samples from 226 atrial fibrillation patients on anticoagulation and 24 samples without anticoagulation serving as controls. As comparators, we measured the international normalized ratio (INR) for phenprocoumon samples (N = 166), anti-Xa for low molecular weight heparin (LMWH) samples (N = 42), and DOAC levels with mass spectrometry (dabigatran N = 40, rivaroxaban N = 110, apixaban N = 42)...
February 7, 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29407959/the-selectivity-and-bioavailability-improvement-of-novel-oral-anticoagulants-an-overview
#9
REVIEW
Zhouling Xie, Yongbing Tian, Xiao Lv, Xuan Xiao, Meimiao Zhan, Kai Cheng, Shiyu Li, Chenzhong Liao
Anticoagulants have exhibited a critical role in the prevention and/or treatment of thrombotic diseases. Up to now, kinds of novel oral anticoagulants, inhibiting plasma serine proteases in the coagulation cascade, have been developed to overcome the clinical limitations of classical anticoagulants (like warfarin and heparins). Some of them, such as Apixaban, Rivaroxaban, Edoxaban, and Dabigatran, have been approved by FDA in recent years. This review summarizes the discovery and optimization of representative novel oral anticoagulants with the aim to improve selectivity and bioavailability of compounds...
February 25, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29407632/what-have-we-learned-from-real-world-noac-studies-in-venous-thromboembolism-treatment
#10
REVIEW
Jan Beyer-Westendorf
Venous thromboembolism (VTE) remains a substantial clinical and health-economic burden worldwide and effective anticoagulant treatment is necessary immediately after VTE is suspected to reduce short- and long-term VTE related morbidity and mortality. For decades, low molecular weight heparin (LMWH), fondaparinux and Vitamin K antagonists (VKAs) have been the standard of anticoagulant therapy for VTE patients but these treatment options had clinically relevant drawbacks and limitations. The introduction of non-VKA oral anticoagulants (NOACs) that specifically inhibit either thrombin or factor Xa have resolved many of these drawbacks because these new compounds exhibit a rapid onset and offset of action, fewer food and drug interactions and a predictable anticoagulant effect...
January 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407622/simple-method-for-removing-doacs-from-plasma-samples
#11
T Exner, N Michalopoulos, J Pearce, R Xavier, M Ahuja
AIM: To evaluate a simple method using an adsorbent product (DOAC Stop) for extracting direct oral anti-coagulants (DOACs) from plasmas. METHOD: DOAC Stop was tested on normal and a range of abnormal plasmas initially using activated partial thromboplastin time (APTT) tests and a more DOAC-sensitive Russells viper venom-based clotting test (DOAC Test). Further tests for prothrombin time/International Normalized Ratio (PT/INR), lupus anticoagulants, activated protein C (APC) resistance, antithrombin, plasminogen, protein C and S were carried out on various patient samples...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407620/point-of-care-testing-poct-to-assess-drug-concentration-in-patients-treated-with-non-vitamin-k-antagonist-oral-anticoagulants-noacs
#12
S Padayattil Jose, A Banzato, P Carraro, A Haleh, K Rossi, G Nante, G Denas, G Zoppellaro, V Pengo
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) do not need routine laboratory monitoring but measurement of drug concentration is important in emergency conditions. Specific laboratory tests are not readily available or not implemented in every hospital. Point-of-Care Tests (POCT) may bridge this gap and be used as a bedside solution. OBJECTIVES: Feasibility of POCT to assess plasma levels of dabigatran, rivaroxaban and apixaban. PATIENTS/METHODS: Activated Coagulation Time-Low Range (ACT - LR) using a portable Hemochron Signature Elite for dabigatran and prothrombin time (expressed as INR) by Coaguchek XS Pro for rivaroxaban and apixaban were obtained at trough and peak in 136 consecutive patients taking NOACs (70 on dabigatran, 45 on rivaroxaban and 20 on apixaban)...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29398546/initiation-and-continuation-of-oral-anticoagulant-prescriptions-for-stroke-prevention-in-non-valvular-atrial-fibrillation-a-cohort-study-in-primary-care-in-france
#13
Shuk-Li Collings, Virginie Vannier-Moreau, Michelle E Johnson, Gillian Stynes, Cinira Lefèvre, Andrew Maguire, Joelle Asmar, Geoffray Bizouard, Didier Duhot, Frédéric Mouquet, Laurent Fauchier
BACKGROUND: Oral anticoagulants are prescribed in non-valvular atrial fibrillation for stroke prevention; however, little is known about the current management of anticoagulation in France, particularly given the availability of non-vitamin K antagonist oral anticoagulants in recent years. AIMS: To describe the characteristics of patients prescribed oral anticoagulants, and assess treatment persistence in French primary care. METHODS: We conducted a cohort study of patients with non-valvular atrial fibrillation, who were newly prescribed oral anticoagulants between 1 January 2014 and 31 January 2016, using French primary care data (IMS Longitudinal Patient Database)...
February 2, 2018: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/29397310/characteristics-of-symptomatic-intracerebral-hemorrhage-in-patient-receiving-direct-oral-anticoagulants-comparison-with-warfarin
#14
Masahito Kawabori, Yoshimasa Niiya, Motoyuki Iwasaki, Shoji Mabuchi, Hiroyuki Ozaki, Koji Matsubara, Kiyohiro Houkin
BACKGROUND: Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset time of ICH in patient taking DOAC are not fully elucidated. METHODS: We retrospectively analyzed the characteristics of symptomatic patients with ICH taking either DOAC or warfarin between January 2012 and December 2015...
January 31, 2018: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29395704/personalized-anticoagulation-guided-apixaban-dose-adjustment-to-compensate-for-pharmacokinetic-abnormalities-related-to-short-bowel-syndrome
#15
P Timothy Pollak, Gavin R Sun, Richard B Kim
A 45-year-old woman who required lifelong anticoagulation for recurrent thrombosis had her therapeutic choices limited by heparin-induced thrombocytopenia and abnormal pharmacokinetics (greatly reduced absorption) resulting from short gut syndrome from extensive gut resection after mesenteric thrombosis. As an alternative to inconvenient and expensive injections of fondaparinux, personalized dosing of a direct oral anticoagulant was sought using clinical pharmacology techniques. Enteral absorption was ascertained with small test doses of apixaban, and the ability of supraconventional doses to deliver effective concentrations was verified...
December 27, 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29395644/risk-of-recurrent-ischemic-stroke-with-unintended-low-dose-oral-anticoagulant-therapy-and-optimal-timing-of-review
#16
Narihide Shinoda, Masafumi Mori, Shogo Tamura, Kazuyoshi Korosue, Shigeru Kose, Eiji Kohmura
BACKGROUND: Direct oral anticoagulant (DOAC) dose is adjusted according to manufacturer's recommendations when introduced. However, subsequent changes from appropriate DOAC doses to "unintended" inappropriate low-dose DOAC (ILD) due to increased body weight (BW) or decreased serum creatinine concentration might be overlooked. We investigated outcomes in patients receiving appropriate DOAC, "intended" ILD, or unintended ILD, to determine the optimal review time for DOAC doses and associated factors...
January 29, 2018: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29391782/comparison-of-claims-vs-patient-reported-adherence-measures-and-associated-outcomes-among-patients-with-nonvalvular-atrial-fibrillation-using-oral-anticoagulant-therapy
#17
Judith J Stephenson, Mayura U Shinde, Winghan Jacqueline Kwong, An-Chen Fu, Hiangkiat Tan, William S Weintraub
Objective: To compare oral anticoagulant (OAC) adherence among patients with nonvalvular atrial fibrillation (NVAF) using patient-reported and claims-based measures, and to evaluate the effect of OAC adherence on health care costs and patient satisfaction with OAC therapy. Methods: This was a hybrid US observational study consisting of a longitudinal cohort survey followed by linkage and analysis of respondents' administrative claims data. Patients with NVAF receiving warfarin, dabigatran, rivaroxaban, or apixaban completed an initial survey and follow-up surveys at 4, 8, and 12 months...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29387335/contemporary-utilization-of-antithrombotic-therapy-for-stroke-prevention-in-patients-with-atrial-fibrillation-an-audit-in-an-australian-hospital-setting
#18
Ekta Yogeshkumar Pandya, Elizabeth Anderson, Clara Chow, Yishen Wang, Beata Bajorek
Background: To document antithrombotic utilization in patients with nonvalvular atrial fibrillation (NVAF), particularly, recently approved NOACs (nonvitamin K antagonist oral anticoagulants) and warfarin; and identify factors predicting the use of NOACs versus warfarin. Methods: A retrospective audit was conducted in an Australian hospital. Data pertaining to inpatients diagnosed with atrial fibrillation (AF) admitted between January and December 2014 were extracted...
February 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29381951/watchman-device-related-thrombus-successfully-treated-with-apixaban-a-case-report
#19
Chun-Ka Wong, Pak-Hei Chan, Cheung-Chi Lam, On-Hing Kwok, Yat-Yin Lam, Chung-Wah Siu
RATIONALE: Among atrial fibrillation patients with high risk of bleeding, left atrial appendage occlusion has emerged as an alternative to long-term oral anticoagulation therapy for stroke prevention. Device-related thrombus remains a major concern because it may result in recurrent embolic events. To date, there is no consensus on the optimal method of treating device-related-thrombus. PATIENT CONCERNS: A 78-year-old man with atrial fibrillation had an episode of intracranial hemorrhage while taking warfarin...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29381944/hemorrhagic-pericardial-effusion-as-the-debut-of-acquired-hemophilia-in-a-chronic-lymphocytic-leukemia-patient-a-case-report-and-a-review-of-acquired-hemophilia-a-related-hematological-malignancies
#20
José María Bastida, María Teresa Cano-Mozo, Felix Lopez-Cadenas, Victor Eduardo Vallejo, Soraya Merchán, Cecilia Santos-Montón, David González-Calle, Javier Carrillo, Ana Africa Martín, Jose Angel Torres-Hernández, Marcos González, Francisco Martín-Herrero, Pedro Pabón, Jose Ramon González-Porras
BACKGROUND: Acquired hemophilia A (AHA) is a rare bleeding disease caused by autoantibodies against factor VIII. Spontaneous bleeding symptoms usually affect the skin and muscle, while pericardial effusion is an extremely rare manifestation. In the elderly, anticoagulant treatment is frequent and bleeding symptoms are usually associated with this. CLINICAL FINDINGS: We report a hemorrhagic pericardial effusion as the AHA debut in a patient with untreated chronic lymphocytic leukemia and anticoagulated with apixaban for atrial fibrillation and chronic arterial ischemia...
November 2017: Medicine (Baltimore)
keyword
keyword
120043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"